LONDON--AstraZeneca PLC (AZN.LN) said Friday the application for a drug for the treatment of high potassium levels in blood is under review by the U.S. food and drug administration after it had inspected the manufacturing facility where the drug is being developed.

AstraZeneca said it is working to solve the matters under review.

-Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

March 17, 2017 03:24 ET (07:24 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AstraZeneca Charts.